Summary of Study ST003432

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001941. The data can be accessed directly via it's Project DOI: 10.21228/M8TM76 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003432
Study TitleIntracellular and medium metabolomics of BT-474 cells treated with LW6
Study SummaryBT-474 human breast cancer cells were treated with various concentrations of LW6 for 24 h.
Institute
Wistar Institute
DepartmentMolecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center
LaboratorySchug's Lab
Last NameMukha
First NameDzmitry
Address3601 Spruce St, Philadelphia, PA 19104, USA
Emaildmukha@wistar.org
Phone+12154956903
Submit Date2024-08-21
Num Groups15
Total Subjects45
PublicationsSubmission Pending
Raw Data AvailableYes
Raw Data File Type(s)mzML, wiff
Analysis Type DetailLC-MS
Release Date2024-09-12
Release Version1
Dzmitry Mukha Dzmitry Mukha
https://dx.doi.org/10.21228/M8TM76
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001941
Project DOI:doi: 10.21228/M8TM76
Project Title:The shutdown of NADH oxidation via Respiratory Complex I mimics fatty acid biosynthesis inhibition
Project Type:LC-MS Quantitative Analysis
Project Summary:Proliferating cancer cells actively utilize anabolic processes for biomass production, including de novo biosynthesis of amino acids, nucleotides, and fatty acids. The key enzyme of the fatty acid biosynthesis pathway, fatty acid synthase (FASN), is widely recognized as a promising therapeutic target in cancer and other health conditions. Here, we establish a metabolic signature of FASN inhibition using a panel of pharmacological inhibitors (GSK2194069, TVB-2640, TVB-3166, C75, cerulenin, and Fasnall). We find that the activity of some commonly used FASN inhibitors is inconsistent with the metabolic signature of FASN inhibition (accumulation of malonate, succinate, malonyl coenzyme A, succinyl coenzyme A, and other metabolic perturbations). Moreover, we show that one of these putative FASN inhibitors, Fasnall, is a respiratory Complex I inhibitor that mimics FASN inhibition through NADH accumulation and consequent depletion of the tricarboxylic acid cycle metabolites. We demonstrate that Fasnall impairs tumor growth in several oxidative phosphorylation-dependent cancer models, including combination therapy-resistant melanoma patient-derived xenografts. Fasnall administration does not reproduce neurological side effects in mice reported for other Complex I inhibitors. Our results have significant implications for understanding the FASN role in human health and disease and provide evidence of therapeutic potential for Complex I inhibitors with fast systemic clearance. Our findings also highlight the continuing need for validation of small molecule inhibitors to distinguish high-quality chemical probes and to expand the understanding of their application.
Institute:Wistar Institute
Department:Molecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center
Laboratory:Schug's Lab
Last Name:Mukha
First Name:Dzmitry
Address:3601 Spruce St., Philadelphia, Pennsylvania 19104, USA
Email:dmukha@wistar.org
Phone:+12154956903
Funding Source:This work was supported by grants from the National Institutes of Health (NIH) National Cancer Institute (NCI) DP2 CA249950-01 (Z.T.S.), NIH NCI P01 CA114046 (Z.T.S.), Melanoma Research Foundation 717173 (Z.T.S.), and Susan G. Komen CCR19608782 (Z.T.S.).
Publications:Submission Pending
Contributors:Dzmitry Mukha, Jena Dessain, Seamus O’Connor, Katherine Pniewski, Fabrizio Bertolazzi, Jeet Patel, Mary Mullins, Zachary T. Schug

Subject:

Subject ID:SU003559
Subject Type:Cultured cells
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:60
Gender:Female
Cell Strain Details:BT-474, breast cancer cell line

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Sample Type Drug Treatment
SA37796604 BT-474 LW6 0.1 uM cellsBT-474 breast cancer cells Intracellular 0.1 uM LW6
SA37796711 BT-474 LW6 0.1 uM cellsBT-474 breast cancer cells Intracellular 0.1 uM LW6
SA37796818 BT-474 LW6 0.1 uM cellsBT-474 breast cancer cells Intracellular 0.1 uM LW6
SA37797216 BT-474 LW6 100 uM cellsBT-474 breast cancer cells Intracellular 100 uM LW6
SA37797323 BT-474 LW6 100 uM cellsBT-474 breast cancer cells Intracellular 100 uM LW6
SA37797409 BT-474 LW6 100 uM cellsBT-474 breast cancer cells Intracellular 100 uM LW6
SA37796905 BT-474 LW6 1 uM cellsBT-474 breast cancer cells Intracellular 1 uM LW6
SA37797019 BT-474 LW6 1 uM cellsBT-474 breast cancer cells Intracellular 1 uM LW6
SA37797112 BT-474 LW6 1 uM cellsBT-474 breast cancer cells Intracellular 1 uM LW6
SA37797521 BT-474 LW6 20 uM cellsBT-474 breast cancer cells Intracellular 20 uM LW6
SA37797607 BT-474 LW6 20 uM cellsBT-474 breast cancer cells Intracellular 20 uM LW6
SA37797714 BT-474 LW6 20 uM cellsBT-474 breast cancer cells Intracellular 20 uM LW6
SA37798115 BT-474 LW6 50 uM cellsBT-474 breast cancer cells Intracellular 50 uM LW6
SA37798208 BT-474 LW6 50 uM cellsBT-474 breast cancer cells Intracellular 50 uM LW6
SA37798322 BT-474 LW6 50 uM cellsBT-474 breast cancer cells Intracellular 50 uM LW6
SA37797820 BT-474 LW6 5 uM cellsBT-474 breast cancer cells Intracellular 5 uM LW6
SA37797913 BT-474 LW6 5 uM cellsBT-474 breast cancer cells Intracellular 5 uM LW6
SA37798006 BT-474 LW6 5 uM cellsBT-474 breast cancer cells Intracellular 5 uM LW6
SA37798417 BT-474 LW6 Veh cellsBT-474 breast cancer cells Intracellular Control
SA37798510 BT-474 LW6 Veh cellsBT-474 breast cancer cells Intracellular Control
SA37798603 BT-474 LW6 Veh cellsBT-474 breast cancer cells Intracellular Control
SA37798734 BT-474 LW6 0.1 uM medBT-474 breast cancer cells Medium 0.1 uM LW6
SA37798842 BT-474 LW6 0.1 uM medBT-474 breast cancer cells Medium 0.1 uM LW6
SA37798926 BT-474 LW6 0.1 uM medBT-474 breast cancer cells Medium 0.1 uM LW6
SA37799347 BT-474 LW6 100 uM medBT-474 breast cancer cells Medium 100 uM LW6
SA37799439 BT-474 LW6 100 uM medBT-474 breast cancer cells Medium 100 uM LW6
SA37799531 BT-474 LW6 100 uM medBT-474 breast cancer cells Medium 100 uM LW6
SA37799035 BT-474 LW6 1 uM medBT-474 breast cancer cells Medium 1 uM LW6
SA37799127 BT-474 LW6 1 uM medBT-474 breast cancer cells Medium 1 uM LW6
SA37799243 BT-474 LW6 1 uM medBT-474 breast cancer cells Medium 1 uM LW6
SA37799645 BT-474 LW6 20 uM medBT-474 breast cancer cells Medium 20 uM LW6
SA37799737 BT-474 LW6 20 uM medBT-474 breast cancer cells Medium 20 uM LW6
SA37799829 BT-474 LW6 20 uM medBT-474 breast cancer cells Medium 20 uM LW6
SA37800238 BT-474 LW6 50 uM medBT-474 breast cancer cells Medium 50 uM LW6
SA37800330 BT-474 LW6 50 uM medBT-474 breast cancer cells Medium 50 uM LW6
SA37800446 BT-474 LW6 50 uM medBT-474 breast cancer cells Medium 50 uM LW6
SA37799936 BT-474 LW6 5 uM medBT-474 breast cancer cells Medium 5 uM LW6
SA37800028 BT-474 LW6 5 uM medBT-474 breast cancer cells Medium 5 uM LW6
SA37800144 BT-474 LW6 5 uM medBT-474 breast cancer cells Medium 5 uM LW6
SA37800533 BT-474 LW6 Veh medBT-474 breast cancer cells Medium Control
SA37800625 BT-474 LW6 Veh medBT-474 breast cancer cells Medium Control
SA37800741 BT-474 LW6 Veh medBT-474 breast cancer cells Medium Control
SA37800850 BlankNA Blank NA
SA37800901 BlankNA Blank NA
SA37801024 RPMI with dFBSNA Medium Control
SA37801140 RPMI with dFBSNA Medium Control
SA37801248 RPMI with dFBSNA Medium Control
SA37801332 RPMI with dFBSNA Medium Control
SA37801449 DMEM/F12 no addsNA QC NA
SA37801502 DMEM/F12 no addsNA QC NA
Showing results 1 to 50 of 50

Collection:

Collection ID:CO003552
Collection Summary:For intracellular metabolite samples, the medium was aspirated, and cells were washed with PBS volume matching the volume of the medium. Metabolites were extracted with ice-cold 80% methanol. The volume of the solvent was 500 µl per 6-cm Petri dish (scaled according to the ratio of surface areas for other cell containers). After adding the methanol solution, cells were scraped from the plates, and all the content was transferred to Eppendorf tubes.
Collection Protocol Filename:DM_metabolomics_samples.txt
Sample Type:Breast cancer cells
Collection Method:80% methanol extraction
Storage Conditions:-80℃
Collection Vials:1.5 ml plastic centrifuge tubes
Storage Vials:1.5 ml plastic centrifuge tubes

Treatment:

Treatment ID:TR003568
Treatment Summary:Cells were grown in RPMI-1640 supplemented with 10% dialyzed FBS and treated with various concentrations of LW6 for 24 h.
Treatment Compound:LW6
Treatment Vehicle:DMSO
Cell Growth Container:6-cm Petri dishes
Cell Media:RPMI-1640
Cell Envir Cond:37C, 5% CO2
Cell Pct Confluence:~70%
Cell Media Lastchanged:24 h before collection

Sample Preparation:

Sampleprep ID:SP003566
Sampleprep Summary:Intracellular metabolites were extracted with ice-cold 80% methanol, and medium samples were extracted with 100% methanol. The samples were centrifuged at 18,000 g 4C for 20 min. After transferring the supernatant to new tubes, centrifugation was repeated with the same parameters.
Sampleprep Protocol Filename:DM_metabolomics_samples.txt
Processing Storage Conditions:4℃
Extraction Method:80% methanol
Extract Enrichment:None
Extract Cleanup:None
Extract Storage:-80℃
Sample Resuspension:None
Sample Derivatization:None
Sample Spiking:None
Subcellular Location:Intracellular metabolites and medium metabolites

Combined analysis:

Analysis ID AN005637 AN005638
Analysis type MS MS
Chromatography type HILIC HILIC
Chromatography system Shimadzu 20AD Shimadzu 20AD
Column Merck SeQuant ZIC-HILIC (150 x 2.1mm,5um) Merck SeQuant ZIC-HILIC (150 x 2.1mm,5um)
MS Type ESI ESI
MS instrument type Triple quadrupole Triple quadrupole
MS instrument name ABI Sciex 5500 QTrap ABI Sciex 5500 QTrap
Ion Mode NEGATIVE POSITIVE
Units Counts per second (cps) Counts per second (cps)

Chromatography:

Chromatography ID:CH004281
Instrument Name:Shimadzu 20AD
Column Name:Merck SeQuant ZIC-HILIC (150 x 2.1mm,5um)
Column Pressure:900-3000 psi
Column Temperature:40
Flow Gradient:0-12.5 min, 80-30% B; 12.5-15 min, 30% B; 15-15.2 min, 30-80% B; 15.2-22.5 min, 80% B
Flow Rate:0-20 min, 0.2 ml/min; 20-21 min 0.2-0.3 ml/min; 21-22 min, 0.3 ml/min; 22-22.1 min, 0.2 ml/min; 22.1-22.5 min, 0.2 ml/min
Injection Temperature:4
Sample Injection:1-5 ul
Solvent A:100% Water; 0.01% ammonium hydroxide; 20 mM ammonium bicarbonate
Solvent B:100% Acetonitrile
Chromatography Type:HILIC

MS:

MS ID:MS005361
Analysis ID:AN005637
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:Data were analyzed with SCIEX Multiquant 3.0.3.
Ion Mode:NEGATIVE
Capillary Temperature:500 °C
Capillary Voltage:-4500
Dry Gas Flow:70
Dry Gas Temp:500 °C
Ion Source Temperature:500 °C
Ion Spray Voltage:-4500
Mass Accuracy:UNIT
Source Temperature:500 °C
Spray Voltage:-4500
Desolvation Gas Flow:70
Desolvation Temperature:500 °C
  
MS ID:MS005362
Analysis ID:AN005638
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:Data were analyzed with SCIEX Multiquant 3.0.3.
Ion Mode:POSITIVE
Capillary Temperature:500 °C
Capillary Voltage:4500
Dry Gas Flow:70
Dry Gas Temp:500 °C
Ion Source Temperature:500 °C
Ion Spray Voltage:4500
Mass Accuracy:UNIT
Source Temperature:500 °C
Spray Voltage:4500
Desolvation Gas Flow:70
Desolvation Temperature:500 °C
  logo